Skip to content

Released Nov 4, 2025, before the open

10-Q filed Nov 4, 2025, 35 days after period end · 0001785530-25-000031

Q3 2025 · 10-Q
Revenue—
Net Income-$16.37MN/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.36N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$15,726,000N/M
Operating Cash Flowderived-$15,156,000N/M
Free Cash Flowderived-$15,156,000N/M

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023Q3 2022
Net Income-$16.37M-$16.67M-$8.29M-$11.94M
EPS Diluted-$0.36-$0.38-$0.23-$0.40

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR